2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK
  5. CDK14 Isoform
  6. CDK14 Inhibitor

CDK14 Inhibitor

CDK14 Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-X0009
    Tambiciclib
    		Inhibitor 99.21%
    Tambiciclib (GFH009, JSH-009) is an orally active, highly potent and selective CDK9 inhibitor (IC50 = 1 nM), demonstrating >200-fold selectivity over other CDKs, >100-fold selectivity over DYRK1A/B, and excellent selectivity over 468 kinases/mutants. Tambiciclib demonstrates potent in vitro and in vivo antileukemic efficacy in acute myeloid leukemia (AML) mouse models by inhibiting RNA Pol II phosphorylation, downregulating MCL1 and MYC, and inducing apoptosis. Tambiciclib can be used for AML research.
  • HY-127104
    FMF-04-159-2
    		Inhibitor 99.64%
    FMF-04-159-2 is a covalent CDK14 inhibitor. FMF-04-159-2 inhibits CDK14 and CDK2 with IC50s of 39.6 nM and 256 nM in NanoBRET assay, respectively.
  • HY-X0150
    JSH-150
    		Inhibitor 98.36%
    JSH-150 is a highly selective and potent CDK9 inhibitor with an IC50 of 1 nM.
  • HY-X0009A
    Tambiciclib dimaleate
    		Inhibitor 99.53%
    Tambiciclib (GFH009, JSH-009) dimaleate is an orally active, highly potent and selective CDK9 inhibitor (IC50 = 1 nM), demonstrating >200-fold selectivity over other CDKs, >100-fold selectivity over DYRK1A/B, and excellent selectivity over 468 kinases/mutants. Tambiciclib dimaleate demonstrates potent in vitro and in vivo antileukemic efficacy in acute myeloid leukemia (AML) mouse models by inhibiting RNA Pol II phosphorylation, downregulating MCL1 and MYC, and inducing apoptosis. Tambiciclib dimaleate can be used for AML research.
  • HY-160213
    JA397
    		Inhibitor
    JA397, a chemical probe, is a potent and selective inhibitor for the TAIRE family with cellular activity ranging from IC50 values of 21 nM to 307 nM.